Geographies in Depth

Everything we know about the Indian COVID-19 variant so far

Notices about the shortage of COVISHIELD, a coronavirus disease (COVID-19) vaccine manufactured by Serum Institute of India, are seen outside a COVID-19 vaccination centre in Mumbai, India

India is witnessing a surge in COVID-10 cases. Image: REUTERS/Francis Mascarenhas

Grace C Roberts
Research Fellow in Virology, Queen's University Belfast
Our Impact
What's the World Economic Forum doing to accelerate action on Geographies in Depth?
The Big Picture
Explore and monitor how Pandemic Preparedness and Response is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Pandemic Preparedness and Response

  • Coronavirus cases have risen sharply in India and a new COVID-19 variant has emerged there called B1617.
  • Scientists think the B1617 variant is more contagious, because of a mutation it carries called L452R, which helps the virus’s spike protein unlock our cells.
  • Just because the virus spreads more easily, doesn't mean it's more deadly.
  • B1617 also carries a second mutation, called E484Q, that changes the spike protein, which may make the virus less susceptible to pre-existing antibodies.
  • The main concern with the Indian variant is the potential for reduced vaccine efficacy.

British prime minister Boris Johnson has cancelled his trip to India, with the country being added to the UK’s “red list” of restricted destinations. COVID-19 cases in India are rising sharply and a specific variant of the virus – B1617 – is becoming increasingly common there.

B1617 has also been found outside of India, including in the UK. Cases in Britain appear to be doubling each week: there are currently 182 in the UK, up from 77 the week before. Right now the variant is “under investigation”, but unlike the Kent (B117), South African (1351) and Brazilian (P1) variants hasn’t been designated a “variant of concern”.

Have you read?

Does this mean this variant is different from the others and we need not be worried? Here’s what we know about its effects so far.

Is this variant more infectious?

We think this variant may be able to spread more easily than earlier forms of the virus. This is because of a mutation it carries called L452R, which affects the virus’s spike protein. This is the “key” the coronavirus uses to unlock our cells.

The L452R mutation changes the part of the spike protein that directly interacts with ACE2, the molecule on the surface of our cells that the virus binds with to get inside. Early research – yet to be reviewed by other scientists – suggests the L452R mutation allows the virus to bind to cells more stably. In previous variants, such as the Kent variant, mutations like this that enhanced the virus’s binding ability resulted in it becoming more infectious.

The B1427 variant detected in California contains the same L452R mutation a B1617. It is estimated to be around 20% more transmissible than the earlier form of the coronavirus that was circulating during the first wave.

And is it more dangerous?

Mutations such as L452R that help with binding don’t necessarily result in more severe disease or make the virus more deadly. For example, while the B1427 variant appears to spread more easily, preliminary research didn’t find that it was associated with more severe infections or higher viral loads. The same could apply to B1617, though this still needs to be investigated.

a woman walks past a sign advertising a covid-19 vaccine hub in the UK's westminster abbey
Over 30 million people in the UK have received a first vaccine dose. Image: Andy Rain/EPA-EFE

But a particular concern is the impact B1617 may have on vaccine efficacy. The vast majority of vaccines developed against the coronavirus are based on targeting the spike protein. As the protein is on the outer surface of the virus, this is what your immune system will predominantly “see” during an infection and therefore make effective antibodies against. If mutations change the spike protein’s shape, then these antibodies may become less effective.

Indeed, preliminary studies suggest the L452R mutation could help the virus evade the immune system. On top of this, B1617 carries a second mutation, called E484Q, that changes the spike protein as well. Research suggests that mutations like it (that affect the same area of the spike protein) may also make the virus less susceptible to pre-existing antibodies.

Early, unreviewed studies of these mutations’ effects in B1617 suggest that they do make the variant less susceptible to antibodies generated previously. However, it is important to stress that these findings have only been shown in laboratory experiments and not in actual people.

How worried should we be?

The Indian health ministry has stated that the country’s rise in cases is not linked to these mutations, as B1617’s mutations haven’t been detected in high enough quantities to determine whether it is directly responsible. However, this may be due to lack of data, and many experts have stressed the importance of increasing virus sequencing to get a better picture.

It’s still too early to tell if this variant will pose a significant threat to efforts to control the virus. However, as always with public health, prevention is better than a cure. Hence, we should continue our efforts to control the virus, both in terms of regulations – masks, social distancing and so on – as well as vaccination, mass testing and genome sequencing. By continuing to combat the virus in general, we can restrict any impact this variant has.

a couple push their suitcases in an airport
From April 23, UK arrivals from India who don’t have British residency or a British or Irish passport will be refused entry. Image: Facundo Arrizabalaga/EPA-EFE

The biggest cause for concern would be if B1617 undermined vaccination efforts. If this variant is able to cause disease in vaccinated individuals, it poses the risk of creating large-scale outbreaks around the world in the future.

Work to create booster vaccinations to deal with current and future variants is already underway, but it is too early to say whether they will be needed to control B1617 specifically.

However, a more effective way to prevent variants causing issues around the world would be to prevent them from spreading in the first place. Strict travel restrictions, such as those seen in New Zealand and Australia, may seem a burden, but have allowed relative normality to return in these countries with little fear of variants disrupting efforts to get back to normal. It’s with this hope that the UK has added India to its red list – essentially banning travel from the country.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
Geographies in DepthHealth and Healthcare Systems
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Asia-Pacific: How the region is prioritizing a green economy

Kanni Wignaraja and Debora Comini

June 10, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum